Journal
PSYCHIATRIC SERVICES
Volume 60, Issue 11, Pages 1466-1467Publisher
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/ps.2009.60.11.1466
Keywords
-
Ask authors/readers for more resources
STAR*D (Sequenced Treatment Alternatives to Relieve Depression) continues to stimulate debate. The landmark trial demonstrated the feasibility of large-scale, community-based studies conducted without pharmaceutical company support. The results provided insight into nonresponse to initial treatment with selective serotonin reuptake inhibitors and alternatives for second-and third-line treatment options and suggested opportunities for personalized approaches to depression care. However, initial and one-year remission rates (28% and 70%, respectively) suggest that important goals for treatment of this disabling disease remain out of reach and that the bar for antidepressants has been set far too low. (Psychiatric Services 60: 1466-1467, 2009)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available